New Experimental Modalities in the Control of Neoplasia: NATO Science Series A:, cartea 120
Editat de Prakash Chandraen Limba Engleză Paperback – 12 dec 2012
Din seria NATO Science Series A:
- 5%
Preț: 373.22 lei - 15%
Preț: 629.85 lei - 15%
Preț: 631.23 lei - 15%
Preț: 652.15 lei -
Preț: 382.30 lei - 5%
Preț: 363.51 lei -
Preț: 382.65 lei - 18%
Preț: 1184.45 lei - 5%
Preț: 703.40 lei -
Preț: 397.45 lei - 15%
Preț: 624.14 lei - 5%
Preț: 355.43 lei -
Preț: 392.06 lei - 5%
Preț: 2077.80 lei -
Preț: 391.91 lei -
Preț: 381.34 lei - 15%
Preț: 638.29 lei -
Preț: 372.67 lei -
Preț: 378.21 lei -
Preț: 383.23 lei -
Preț: 385.99 lei - 15%
Preț: 652.60 lei -
Preț: 380.09 lei - 18%
Preț: 915.43 lei - 15%
Preț: 629.18 lei -
Preț: 386.74 lei - 15%
Preț: 629.98 lei -
Preț: 379.71 lei -
Preț: 369.90 lei - 5%
Preț: 380.56 lei - 5%
Preț: 1366.27 lei - 15%
Preț: 626.20 lei -
Preț: 384.90 lei -
Preț: 372.31 lei - 5%
Preț: 371.42 lei -
Preț: 388.57 lei - 15%
Preț: 626.36 lei -
Preț: 378.95 lei - 5%
Preț: 362.13 lei -
Preț: 385.06 lei - 5%
Preț: 374.06 lei -
Preț: 385.44 lei - 5%
Preț: 711.99 lei - 18%
Preț: 1177.49 lei - 5%
Preț: 371.77 lei
Preț: 385.99 lei
Nou
Puncte Express: 579
Preț estimativ în valută:
68.30€ • 79.65$ • 59.97£
68.30€ • 79.65$ • 59.97£
Carte tipărită la comandă
Livrare economică 16-30 ianuarie 26
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781468452440
ISBN-10: 1468452444
Pagini: 420
Ilustrații: XI, 402 p. 80 illus.
Dimensiuni: 178 x 254 x 22 mm
Greutate: 0.73 kg
Ediția:Softcover reprint of the original 1st ed. 1986
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
ISBN-10: 1468452444
Pagini: 420
Ilustrații: XI, 402 p. 80 illus.
Dimensiuni: 178 x 254 x 22 mm
Greutate: 0.73 kg
Ediția:Softcover reprint of the original 1st ed. 1986
Editura: Springer Us
Colecția Springer
Seria NATO Science Series A:
Locul publicării:New York, NY, United States
Public țintă
ResearchCuprins
1. A Developmental Biologist’s View of Cancer.- 2. Oncogenes in Development, Neoplasia and Evolution.- 3. Acquisition of Metastatic Properties via Somatic Cell Fusion: Implications for Tumor Progression in vivo.- 4. Oncogenes and Tyrosine Kinase Activities as a Function of the Metastatic Phenotype.- 5. Immune Reactivities During the Precancer and Early Cancer Periods: Novel Approaches for Immunomodulation.- 6. Immunomodulation of Tumor Metastases.- 7. Monoclonal Antibody Targeting of Anti-Cancer Agents.- 8. Treatment of Human B Cell Lymphoma with Monoclonal Anti-Idiotype Antiboaies.- 9. Human Monoclonal Antibodies Directed Against HuMTV Antigens form Human Breast Cancer Cells.- 10. Recent Advances in Thymic Hormone Research.- 11. T-Cell Growth Factor (Interleukin -2).- 12. Drug Resistance: New Approaches to Treatment.- 13. Mechanisms of Membrane-Mediated Cytotoxicity by Adriamycin.- 14. Terminal Transferase and Adenosine Deaminase Activities in Human Neoplasia: Their Role in Modulating Cancer Treatment.- 15. Inhibitors of Terminal Transerase: A New Strategy for the Treatment of Human Leukemia.- 16. DNA-Protein Crosslinking of Platinum Coordination Complex in Living Cells: Implication to Evaluate the Cytotoxic Effects of Chemotherapeutic Agents.- 17. Antitumor Activity, Pharmacology and Clinical Trials of Elliptinium (NSC 264–137).- 18. Therapeutic Efficacy of Oxazaphosphorines by Immunomodulation.- 19. The Role of Cellular Glutathione in Protecting Mammalian Cells from X Radiation and Chemotherapy Agents in vitro.- 20. The Role of Papilloma Viruses in Human Cancer.- 21 Anti-Viral Vaccine Control of EB Virus-Associated Cancers.- 22. Bovine Leukosis Virus as a Model for Human Retroviruses.- 23. Human T-Lymphotropic Retroviruses and their Role in Human Diseases.- 24.Molecular Biology of the Human T-Lymphotropic Retroviruses.- 25. Antiviral Approaches in the Treatment of Acquired Immune Deficiency Syndrome.- 26. Inhibition of HTLV-III Replication in Cell Cultures.- 27. Proteins Encoded by the Human T-Lymphotropic Virus Type III/Lymphadenopathy Associated Virus (HTLV-III/LAV) Genes.- 28. Cytopathogenic Mechanisms which Lead to Cell Death of HTLV-III Infected T. Cells.- 29. Clinical Aspects of Thymic Factors in the Treatment of Immunodeficiency Diseases and Neoplasia: Achievements and Failures.- 30. An Overview of the Current Understanding and Management of the Non-Hodgkin’s Lymphomas.- Participants.